m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00703)
Name
ischemin
Synonyms
MS120
    Click to Show/Hide
Status
Investigative
Structure
Formula
C15H17N3O4S
InChI
1S/C15H17N3O4S/c1-8-4-10(3)15(23(20,21)22)7-12(8)17-18-13-5-9(2)14(19)6-11(13)16/h4-7,19H,16H2,1-3H3,(H,20,21,22)
InChIKey
UUECJWRVDTUDCB-UHFFFAOYSA-N
PubChem CID
135566302
TTD Drug ID
D00DXI
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
CREB-binding protein (CREBBP)
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary CREB-binding protein (CREBBP) is a therapeutic target for ischemin. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ischemin through regulating the expression of CREB-binding protein (CREBBP). [1], [2]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary CREB-binding protein (CREBBP) is a therapeutic target for ischemin. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ischemin through regulating the expression of CREB-binding protein (CREBBP). [2], [3]
References
Ref 1 N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell. 2015 Jun 4;161(6):1388-99. doi: 10.1016/j.cell.2015.05.014.
Ref 2 Clinical pipeline report, company report or official report of FORMA Therapeutics.
Ref 3 N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014 Jan 2;505(7481):117-20. doi: 10.1038/nature12730. Epub 2013 Nov 27.